Current Hypertension Reports最新文献_第5页

Chemerin as a Mediator of Hypertension and Cardiometabolic Diseases (A Comprehensive Review). 趋化素作为高血压和心脏代谢疾病的介质（综述）。

IF 5.1 2区医学

Current Hypertension Reports Pub Date : 2025-12-29 DOI: 10.1007/s11906-025-01354-3

Ronald McMillan, Annet Kirabo

{"title":"Chemerin as a Mediator of Hypertension and Cardiometabolic Diseases (A Comprehensive Review).","authors":"Ronald McMillan, Annet Kirabo","doi":"10.1007/s11906-025-01354-3","DOIUrl":"10.1007/s11906-025-01354-3","url":null,"abstract":"Purpose: Chemerin, a recently identified adipokine, has emerged as a critical mediator in multiple physiological systems with significant implications for human health and disease. This review synthesizes current knowledge on chemerin's multifaceted roles across cardiovascular, renal, immune, and metabolic processes. Acting through its primary receptor CMKLR1, chemerin influences sympathetic nervous system activity in key brain regions including the nucleus tractus solitarius and paraventricular nucleus, thereby regulating blood pressure and cardiovascular function.Recent findings: In the kidneys, elevated chemerin levels correlate with declining renal function, serving as both a biomarker and pathogenic factor in chronic kidney disease progression and diabetic nephropathy. As an immune modulator, chemerin facilitates leukocyte recruitment, promotes macrophage polarization toward pro-inflammatory phenotypes, and enhances endothelial inflammation, establishing it as a pivotal link between metabolic dysregulation and chronic inflammatory states. Chemerin plays a central role in hypertension by altering endothelial function, renal function and sympathetic outflow. In metabolic regulation, chemerin influences adipocyte differentiation, glucose homeostasis, and central appetite control, connecting obesity with systemic inflammation and insulin resistance. The convergence of these diverse functions positions chemerin as an integrative signaling molecule with considerable therapeutic potential. This review highlights chemerin's role as a promising target for novel interventions in hypertension, kidney disease, inflammatory disorders, and metabolic syndrome, potentially transforming treatment strategies for these interconnected conditions.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"4"},"PeriodicalIF":5.1,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12745319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions. 除血糖控制和体重减轻之外的肥胖药物：扩大益处、临床挑战和未来方向的最新进展。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-12-29 DOI: 10.1007/s11906-025-01349-0

Spyridon Ntelis, Brian S Wojeck

{"title":"Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions.","authors":"Spyridon Ntelis, Brian S Wojeck","doi":"10.1007/s11906-025-01349-0","DOIUrl":"10.1007/s11906-025-01349-0","url":null,"abstract":"Purpose of review: This article summarizes the clinical effects of incretin therapies. We review data from recent clinical trials, beyond glycemic control and weight reduction.Recent findings: Incretin therapies are associated with a lower risk of atherosclerotic cardiovascular events and improved clinical outcomes in patients with heart failure and preserved ejection fraction. Recent studies demonstrate a much wider spectrum of clinical benefits, including nephroprotection in patients with diabetic kidney disease, diabetes prevention, therapeutic potential in the management of metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea, and even neuroprotective effects. Possible adverse events, primarily involving the gastrointestinal system, and the need for long-term continuation are factors that need to be considered before initiation of treatment. Incretin receptor agonists have changed the landscape of diabetes and obesity management. Their clinical benefits expand to a wide spectrum of cardiovascular and metabolic disorders and have major implications for clinical practice.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"5"},"PeriodicalIF":6.3,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Therapeutic Strategies for Obesity-Related Glomerulopathy. 肥胖相关性肾小球病的新治疗策略

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-12-27 DOI: 10.1007/s11906-025-01357-0

YaFei Liu, Alfonso Eirin, Lilach O Lerman

{"title":"Novel Therapeutic Strategies for Obesity-Related Glomerulopathy.","authors":"YaFei Liu, Alfonso Eirin, Lilach O Lerman","doi":"10.1007/s11906-025-01357-0","DOIUrl":"10.1007/s11906-025-01357-0","url":null,"abstract":"PURPOSE OF REVIEW: Conventional management primarily focuses on weight reduction and renin-angiotensin-aldosterone blockade; however, these approaches are often insufficient to halt disease progression. RECENT FINDINGS: Recent advances have identified novel therapeutic targets and strategies aimed at addressing the metabolic, inflammatory, and hemodynamic abnormalities, as well as gut microbiome dysbiosis, driving obesity-related glomerulopathy (ORG). Pharmacological agents like sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, finerenone, mitochondrial transfer, and fecal microbiota transplantation have demonstrated renoprotective effects through improving weight, insulin sensitivity, blood pressure, inflammation, and gut microbiome. The potential direct renoprotective effects of these medications in ORG, independent of weight loss, warrant further investigation. Additionally, artificial intelligence and emerging biomarkers represent promising strategies for personalized and precise management, early non-invasive diagnosis, and prognostic evaluation of ORG. ","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"3"},"PeriodicalIF":6.3,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12865782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity in Cardiorenal syndrome: Management Opportunities and Challenges. 心肾综合征肥胖：管理机遇与挑战。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-12-27 DOI: 10.1007/s11906-025-01352-5

Allison Reaves, Emily Jaffe, Wendy McCallum

{"title":"Obesity in Cardiorenal syndrome: Management Opportunities and Challenges.","authors":"Allison Reaves, Emily Jaffe, Wendy McCallum","doi":"10.1007/s11906-025-01352-5","DOIUrl":"10.1007/s11906-025-01352-5","url":null,"abstract":"Purpose of review: The prevalence of obesity continues to increase globally. There is accumulating evidence of the complex interplay between obesity, cardiovascular disease, particularly heart failure with preserved ejection fraction, and chronic kidney disease (CKD). Here, we review the diagnostic and management considerations for these co-existent conditions and the current evidence regarding the impact of obesity treatments on long term health outcomes.Recent findings: Recent evidence suggests the pathophysiology of obesity, heart failure with preserved ejection fraction and CKD are inextricably linked as adipocytes appear to play a role in promoting renal sodium avidity and volume overload, which are the hallmarks of the cardiorenal syndrome. The clinical landscape of obesity management has changed significantly with the approval of glucagon-like peptide-1 receptor agonists, which have been shown to have cardiovascular and kidney benefit among patients with obesity and a range of comorbid conditions including diabetes, CKD, and heart failure. Improved recognition, diagnosis and management of clinically consequential obesity is emerging as a key factor in improving outcomes for patients with comorbid conditions such as heart failure with preserved ejection fraction and CKD. The incorporation of comprehensive multi-disciplinary management, shared decision making with patients and broader access to therapies is critical to improving clinical outcomes.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"1"},"PeriodicalIF":6.3,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12977100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tracing Human Sympathetic Cardiovascular Control Mechanism in the Brain. 人脑中人类交感心血管控制机制的追踪。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-12-27 DOI: 10.1007/s11906-025-01353-4

Vaughan G Macefield, Luke A Henderson

{"title":"Tracing Human Sympathetic Cardiovascular Control Mechanism in the Brain.","authors":"Vaughan G Macefield, Luke A Henderson","doi":"10.1007/s11906-025-01353-4","DOIUrl":"10.1007/s11906-025-01353-4","url":null,"abstract":"Purpose of review: We review our approach of using MSNA-coupled fMRI to identify how different regions of the brain interact to control blood pressure. By performing functional magnetic resonance imaging (fMRI) of the brain at the same time as recording muscle sympathetic nerve activity (MSNA), via a microelectrode in the common peroneal nerve, we can identify areas of the brain involved in the generation of sympathetic outflow to the muscle vascular bed, a major contributor to blood pressure regulation.Recent findings: Together with functional connectivity analysis of areas identified through MSNA-coupled fMRI, we have established key components of the human sympathetic connectome and their roles in the control of blood pressure. Whilst our studies confirm the roles of nucleus tractus solitarius (NTS), caudal ventrolateral medulla (CVLM) and rostral ventrolateral medulla (RVLM) in the baroreflex-mediated control of MSNA, we have identified cortical areas - dorsolateral prefrontal cortex, precuneus and insula - that are coupled to RVLM via the hypothalamus and midbrain periaqueductal gray (PAG). This emphasizes the roles of areas above the brainstem in the regulation of blood pressure.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"2"},"PeriodicalIF":6.3,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Clinical Significance of Ambulatory Blood Pressure on Cerebral Small Vessel disease. A Systematic Review and meta-analysis of the Literature. 动态血压对脑血管病的临床意义。文献的系统回顾和荟萃分析。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-12-01 DOI: 10.1007/s11906-025-01348-1

Christina Antza, Nikolaos Kakaletsis, Smaro Palaska, Panagiota Anyfanti, Dimitris Triantis, Vasilios Kotsis

{"title":"The Clinical Significance of Ambulatory Blood Pressure on Cerebral Small Vessel disease. A Systematic Review and meta-analysis of the Literature.","authors":"Christina Antza, Nikolaos Kakaletsis, Smaro Palaska, Panagiota Anyfanti, Dimitris Triantis, Vasilios Kotsis","doi":"10.1007/s11906-025-01348-1","DOIUrl":"10.1007/s11906-025-01348-1","url":null,"abstract":"Purpose of review: Blood pressure (BP) is involved in the pathogenesis of cerebral small vessel disease (CSVD) and clinical research confirms this strong correlation. Data showing whether daytime or nighttime BP is the most important variable of CSVD are conflicting. Therefore, the purpose of this meta-analysis is to evaluate the impact daytime and nighttime BP in terms of CSVD correlation. Additionally, we evaluated the role of nocturnal BP variation for the same purpose.Recent findings: We systematically searched PubMed and Scopus databases to extract data evaluating the association between different ABPM components (24 h, day- and nighttime BP, dipping patterns) and imaging features of CSVD (white matter hypersensitivies, lacunes, cerebral microbleeds). Study quality was evaluated with the Newcastle-Ottawa scale. In the qualitative synthesis, 24 studies with 6822 patients were included. The pooled analysis of 19 studies showed that increased 24 h SBP is associated with 41% increased risk of CSVD, and this is consistently observed for both daytime and nighttime SBP. this effect is largely driven by the impact of 24 h, day- and night-time SBP on CMBs. Impaired nocturnal BP patterns are strongly associated with CSVD, specifically non-dipping profile with an OR of 2.24 (95% CI: 1.31-3.16) compared to dipping pattern. Reverse dipping was associated with CMBs with an increased OR of 3.02 (95% CI: 1.61, 4.42). Obtaining information on different components of ABPM (24 h, day- and night-time BP, dipping profile) may allow identification of patients at higher risk for CSVD including its specific subtypes, specifically CMBs.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"27 1","pages":"29"},"PeriodicalIF":6.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists. SGLT2抑制剂和GLP-1受体激动剂的降血压作用。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-12-01 DOI: 10.1007/s11906-025-01342-7

Ahmed Kamal Siddiqi, Muhammad Shahzeb Khan, Anandita Kulkarni, Michael E Hall, Michael Böhm, Javier Díez, Javed Butler

{"title":"Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.","authors":"Ahmed Kamal Siddiqi, Muhammad Shahzeb Khan, Anandita Kulkarni, Michael E Hall, Michael Böhm, Javier Díez, Javed Butler","doi":"10.1007/s11906-025-01342-7","DOIUrl":"10.1007/s11906-025-01342-7","url":null,"abstract":"Purpose of review: Hypertension is the leading modifiable risk factor for cardiovascular disease. Despite multiple antihypertensive therapies, blood pressure (BP) control remains suboptimal in many individuals with persistent cardiovascular risk. This review evaluates the antihypertensive potential of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in patients with comorbid diabetes, HF, CKD or resistant hypertension.Recent findings: SGLT2-i consistently lower office SBP/DBP (2.5-4.0/1.5-2.0 mmHg) and 24-hour ambulatory BP (3.8/1.8 mmHg). GLP-1RAs show modest SBP reductions (1.8-5.1 mmHg) and minimal DBP effects (~ 0.5 mmHg), though tirzepatide shows greater efficacy (~ 10.6 mmHg) in select populations. Both classes have demonstrated cardio-renal benefits, favorable safety profiles, and reduced polypharmacy. SGLT2-i exert more consistent BP-lowering effects than GLP-1RA, largely due to their diuretic-like action. While not first-line therapies, both drug classes show promise as adjuncts in high-risk populations. Future research should further define their role in comprehensive hypertension management.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"27 1","pages":"28"},"PeriodicalIF":6.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Adverse Childhood Experiences on Cardiovascular Health across the Lifespan. 童年不良经历对心血管健康的影响。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-10-23 DOI: 10.1007/s11906-025-01341-8

Ananya Mukundan, Tammy M Brady

引用次数: 0

Which Systolic Blood Pressure Measure Is Most Important for Determining Cardiovascular Risk: Seated or Supine Blood Pressure? 哪种收缩压测量对确定心血管风险最重要：坐位血压还是仰卧血压？

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-10-21 DOI: 10.1007/s11906-025-01346-3

Tomas L Bothe, Abigail E Melloy, Andreas Patzak, Niklas Pilz

{"title":"Which Systolic Blood Pressure Measure Is Most Important for Determining Cardiovascular Risk: Seated or Supine Blood Pressure?","authors":"Tomas L Bothe, Abigail E Melloy, Andreas Patzak, Niklas Pilz","doi":"10.1007/s11906-025-01346-3","DOIUrl":"10.1007/s11906-025-01346-3","url":null,"abstract":"Purpose of review: In clinical practice, the diagnosis of hypertension is based on non-invasive upper-arm cuff blood pressure (BP) measurement. Most measurements are performed seated, although evidence indicates that supine BP may provide additional information. This review summarises recent findings on the influence of body posture on BP readings and cardiovascular (CV) risk prediction across office, ambulatory, and home BP monitoring (OBPM, ABPM, HBPM), their clinical implications and future research directions.Recent findings: In OBPM, patients with supine-only hypertension demonstrated CV risk comparable to patients with hypertensive BP in both positions, and a higher risk than seated-only hypertensives. Supine hypertension was particularly predictive in individuals under 65 years of age. In ABPM, the strongest predictors of CV events are nocturnal hypertension and abnormal dipping patterns, particularly when patients are truly asleep, whereas supine nocturnal HBPM has been less extensively investigated. Current clinical practice remains primarily based on seated BP measurements. Recent trials have highlighted that supine OBPM may provide additional predictive power in the assessment of CV risk. These findings offer a partial explanation for the residual high predictive value of nocturnal BP values which can be derived from ABPM or specialised HBPM devices that goes beyond the correlation of breathing related sleep disorders Research should focus on homogenising supine risk data into composite risk scores combining seated and supine BP while new outcome studies should consider including supine BP measurement. Future guideline committees should consider recommending the structured clinical application of supine BP, given its demonstrated prognostic benefits.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"27 1","pages":"26"},"PeriodicalIF":6.3,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methods for Assessment of Sleep and Circadian Rhythms in Cardiovascular Research. 心血管研究中睡眠和昼夜节律的评估方法。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2025-10-21 DOI: 10.1007/s11906-025-01345-4

Rebecca Williams, Gabrielle Gloston, Katherine C Ward, Shubhi Jain, Kristen Hays, Annie Ensor, Samarth Patel, Neel Patel, Mackenzie Hogue, S Justin Thomas, Brittanny M Polanka

{"title":"Methods for Assessment of Sleep and Circadian Rhythms in Cardiovascular Research.","authors":"Rebecca Williams, Gabrielle Gloston, Katherine C Ward, Shubhi Jain, Kristen Hays, Annie Ensor, Samarth Patel, Neel Patel, Mackenzie Hogue, S Justin Thomas, Brittanny M Polanka","doi":"10.1007/s11906-025-01345-4","DOIUrl":"10.1007/s11906-025-01345-4","url":null,"abstract":"Sleep is recognized in Life's Essential 8™ as an important behavioral factor for improving and maintaining cardiovascular health. While sleep duration is currently the focus in Life's Essential 8™, sleep health is multidimensional and encompasses regularity, satisfaction, next-day alertness, timing, efficiency, and duration. In addition to sleep, circadian factors have also been implicated in cardiovascular health. For example, shift work, which results in significant circadian misalignment, is associated with poor cardiovascular health. This review will describe methods for measuring, analyzing, and interpreting sleep and circadian rhythms in humans. Subjective and objective measurements of sleep are not always concordant and may reflect distinct constructs. Therefore, both subjective and objective sleep measurements are discussed. Assessment of the circadian system in humans typically relies on the measurement of circadian biomarkers (i.e., melatonin, core body temperature, and/or cortisol) during rigorous and burdensome research protocols. However, novel approaches are being developed to estimate circadian parameters with lower cost and participant burden. This review aims to inform cardiovascular scientists and clinicians of common practices in the assessment of sleep and circadian rhythms.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"27 1","pages":"25"},"PeriodicalIF":6.3,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0